Pros | ![]() Among most bought funds within the category. ![]() Larger AUM within category. ![]() Beats FD returns for both 3Y & 5Y duration. | ![]() 5Y returns in the top 25% of the category. ![]() 3Y returns in the top 25% of the category. ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | - |
INDMoney rank | 6/8 | 1/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 12 Years | 12 Years | ||
Fund Size | 8260 Cr | 3671 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹5000 | SIP ₹500 Lumpsum ₹5000 | ||
Expense Ratio | 0.91% | 0.9% | ||
Exit Load | 1% | 0.5% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 41 | 32 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (13.88%) Divi's Laboratories Ltd (9.57%) Lupin Ltd (6.3%) Cipla Ltd (6.01%) Apollo Hospitals Enterprise Ltd (5.48%) | Sun Pharmaceuticals Industries Ltd (13.98%) Divi's Laboratories Ltd (6.63%) Max Healthcare Institute Ltd Ordinary Shares (6.28%) Cipla Ltd (5.07%) Lonza Group Ltd ADR (4.97%) | ||
No of Sectors | 1 | 2 | ||
Top 3 Sectors | Health (100%) | Health (93.68%) Basic Materials (6.32%) | ||
Equity % | 99.71% | 97.4% | ||
Debt % | - | - | ||
P/E | 38.23 | 44.7 | ||
P/B | 6.38 | 6.41 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 2.67% | 1.93% | ||
3-Month Return | 6.48% | 6.72% | ||
6-Month Return | 0.59% | 2.65% | ||
1-Year Return | 16.15% | 22.37% | ||
3-Year Return | 24.5% | 28.88% | ||
5-Year Return | 24.3% | 26.72% |
Sharpe | 0.89 | 1.17 | ||
Alpha | 1.42 | 5.32 | ||
Beta | 0.9 | 0.85 | ||
Standard Deviation | 15.81 | 14.89 | ||
Information Ratio | 0.06 | 1.07 |
Description | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | SBI Healthcare Opportunities Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Sailesh Raj Bhan,Kinjal Desai | Tanmaya Desai |